Shivanand Puthli

Title: The Innovative Journey of Shivanand Puthli

Introduction

Shivanand Puthli, an accomplished inventor residing in Monmouth Junction, NJ, has made significant contributions to the field of pharmaceuticals. With a focus on innovative drug formulations, he holds a noteworthy patent that showcases his expertise and creativity in developing effective medicinal solutions.

Latest Patents

Puthli's patent, titled "Benzonatate Modified Release Solid Tablets and Capsules," represents a remarkable advancement in cough suppressant technology. This invention describes a unique 12-hour anti-tussive modified release solid tablet or a tablet-in-capsule format. It features a benzonatate-silicon dioxide adsorbate powder encapsulated in a hydrophilic matrix, ensuring that there is virtually no benzonatate release in the buccal cavity, alongside a controlled release profile. The technology is designed to release no more than about 1% of benzonatate within the first half hour of in vitro dissolution testing, providing sustained relief for patients.

Career Highlights

Currently, Shivanand Puthli is associated with Tris Pharma, Inc., where he continues to innovate within the pharmaceutical industry. His work at Tris Pharma has enabled him to pioneer developments that enhance drug delivery systems and improve patient care. With only one patent to his name thus far, it's clear that his focus is on quality and groundbreaking advancements in medicinal technology rather than sheer quantity.

Collaborations

Throughout his career, Puthli has collaborated with esteemed colleagues, including Andrea Nelson and Sachin Vasant Chaudhari, who share his dedication to advancing pharmaceutical innovations. These partnerships have allowed for a dynamic exchange of ideas and expertise, furthering their collective impact within the industry.

Conclusion

Shivanand Puthli stands out as a leading figure in pharmaceutical innovation. His patent for benzonatate modified release solid tablets and capsules exemplifies his commitment to improving patient outcomes through science and technology. As he continues his journey at Tris Pharma, the industry looks forward to his future contributions, which promise to enhance the landscape of medicinal treatments.